Plant bio-factories contributing to the COVID-19 fight
Researchers have made the genome of the Nicotiana benthamiana plant, a commonly used bio-factory organism, public to aid in COVID-19 vaccine production.
List view / Grid view
Genomics is the branch of molecular biology concerned with the structure, function, evolution, and mapping of genomes.
Researchers have made the genome of the Nicotiana benthamiana plant, a commonly used bio-factory organism, public to aid in COVID-19 vaccine production.
Austrian researchers reveal the first 21 SARS-CoV-2 viral genomes as part of their project to aid in international understanding of how the virus causing COVID-19 mutates.
Drug Target Review discusses how NETSseq, a novel profiling technology, is bringing new insights to neurodegenerative and psychiatric diseases.
Dr Kutschera discusses the differences between males and females in relation to infection from the COVID-19 coronavirus.
Researchers have used the genome of Erysimum cheiranthoides (wormseed wallflower) to understand how plants biosynthesise cardenolides.
Organoids at different stages of non-alcoholic steatohepatitis (NASH) progression have been created to help in drug design and identification of diagnostic biomarkers.
Researchers have created an accurate mouse model of Duchenne muscular dystrophy (DMD), showing that TGFβ is a potential target for the condition.
The TAp63 tumour suppressor protein, two micro RNAs (miRNAs) and the AURKA gene can all suppress cutaneous squamous cell carcinoma (cuSCC) development, find researchers.
Researchers observed that deleting the IRE1-alpha gene caused beta cells to de-differentiate and then re-differentiate in mice, preventing immune system auto-activation.
Advances in informatics have afforded researchers the ability to extrapolate petabytes of human genomics data and translate it into biologically relevant information. However, further translating this information into knowledge can prove challenging. Slavé Petrovski, Vice President and Head of Genome Analytics and Bioinformatics for AstraZeneca’s Centre for Genomics Research, spoke…
Researchers have used CRISPR-Cas9 to screen the genome for possible targets that could be used in potential treatments for muscular dystrophy.
A study has shown that plasmids use type IV CRISPR-Cas against competing plasmids, leading the researchers to suggest the method as a novel way to tackle multi-drug resistant bacteria.
Detailed knowledge of the human genome can provide us with extensive information about the causes of disease and how patients will respond to treatments. In this article, Pushpanathan Muthuirulan explores the concept of genetic testing and the potential for pharmacogenomic testing to transform healthcare.
The UK government has invested £20 million into the COVID-19 Genomics UK Consortium, which will use whole genome sequencing to inform infection control measures and therapeutic developments.
Included in this In-Depth Focus are articles on why human tissue models are best for testing nephrotoxicity and how genetic and pharmacogenomic testing can improve healthcare options.